INVENTIVA (EPA:IVA) | WebDisclosure

Basculer en Français

10940	Companies
239029	Keywords
167904	Articles
128527	Press releases

Home
Companies
INVENTIVA

BRIEF

published on 07/18/2024 at 08:35, 2 years 1 month ago

Inventiva announces the issuance of royalty certificates for an amount of 20.1 million euros

Biopharmaceutical Inventive Lanifibranor MASH/NASH Royalty Certificates
PRESS RELEASE

published on 07/18/2024 at 08:30, 2 years 1 month ago

Inventiva annonce l'émission de certificats de royalties pour un montant de 20,1 millions d'euros
Inventiva annonce l'émission de certificats de royalties pour un montant de 20,1 millions d'euros, souscrits par Samsara BioCapital et des actionnaires existants pour financer le développement du lanifibranor

Développement Inventiva Lanifibranor Certificats De Royalties Samsara BioCapital
PRESS RELEASE

published on 07/18/2024 at 08:30, 2 years 1 month ago

Inventiva announces a €20.1 million issuance of royalty certificates
Inventiva announces a €20.1 million issuance of royalty certificates to fund lanifibranor development, extending cash runway. Key shareholders involved in the transaction

Strategic Options Inventiva Lanifibranor Royalty Certificates Cash Runway
BRIEF

published on 07/05/2024 at 22:05, 2 years 2 months ago

Inventiva : mise à jour sur le programme clinique NATiV3 et état financier

Financement Essai Clinique Inventiva NASH Lanifibranor
BRIEF

published on 07/05/2024 at 22:05, 2 years 2 months ago

Inventiva: update on the NATiV3 clinical program and financial statement

Funding Clinical Test Inventive NASH Lanifibranor
PRESS RELEASE

published on 07/05/2024 at 22:00, 2 years 2 months ago

Inventiva fait le point sur son programme clinique NATiV3 évaluant lanifibranor dans la MASH/NASH et sur sa situation financièr
Inventiva fait le point sur son programme clinique NATiV3 pour la MASH/NASH et sa situation financière. Recrutement en cours, résultats attendus en 2026

Inventiva NATiV3 NASH MASH Lanifibranor
PRESS RELEASE

published on 07/05/2024 at 22:00, 2 years 2 months ago

Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position
Inventiva updates on its clinical program evaluating lanifibranor for MASH/NASH, with positive recruitment and financial outlook. New patents strengthen the company's position

Financial Position Clinical Program Inventiva Lanifibranor MASH/NASH
BRIEF

published on 06/21/2024 at 22:05, 2 years 2 months ago

Results of the Combined Shareholders' General Meeting of June 20, 2024

Shareholders' Meeting Resolutions Votes Inventiva
BRIEF

published on 06/21/2024 at 22:05, 2 years 2 months ago

Résultats de l'Assemblée Générale Mixte du 20 juin 2024

Resolutions Rencontre D'actionnaires Votes Inventive
PRESS RELEASE

published on 06/21/2024 at 22:05, 2 years 2 months ago

DESCRIPTIF DU PROGRAMME DE RACHAT D’ACTIONS AUTORISE PAR L'ASSEMBLEE GENERALE ORDINAIRE DU 20 JUIN 2024
Descriptif du programme de rachat d'actions autorisé par l'Assemblée générale ordinaire du 20 juin 2024 pour la Société Inventiva SA. Objectifs, modalités et durée du programme présentés conformément à l'article 241-2 du Règlement Général de l'AMF

Marché Financier Contrat De Liquidité Assemblée Générale Ordinaire Programme De Rachat D'actions Inventiva SA

Accesswire

Published on 09/08/2026 at 01:45, 2 hours 48 minutes ago

Tunkillia Environmental Scoping Report Approved
Published on 09/05/2026 at 04:05, 3 days ago

Pelican AI Corp. Announces Proposed Share Issuances and Litigation Update
Published on 09/04/2026 at 23:30, 3 days 5 hours ago

FutureGen Industries Announces Shares for Debt Settlement
Published on 09/04/2026 at 23:00, 3 days 5 hours ago

Golden Minerals Announces Management Change and Argentine Project Update
Published on 09/04/2026 at 22:30, 3 days 6 hours ago

Panther Minerals Closes Brokered Private Placement of $3,000,000

View all ACCESSWIRE

EQS Group

Published on 09/07/2026 at 19:19, 9 hours 14 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Sales and Adjusted EBIT in Q2 2026/27 above prior-year level – FY outlook maintained
Published on 09/07/2026 at 19:00, 9 hours 33 minutes ago

PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 31 août 2026 au 4 septembre 2026
Published on 09/07/2026 at 18:42, 9 hours 51 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/07/2026 at 18:00, 10 hours 33 minutes ago

E-PANGO: e-Pango organise un webinaire avec ses actionnaires
Published on 09/07/2026 at 17:45, 10 hours 48 minutes ago

VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social

Les Echos

Published on 09/07/2026 at 19:55, 8 hours 37 minutes ago

TFF GROUP CREE TFF UPCYCLING
Published on 09/07/2026 at 19:00, 9 hours 33 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 4 septembre 2026
Published on 09/07/2026 at 19:00, 9 hours 33 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of September 4, 2026
Published on 09/07/2026 at 18:05, 10 hours 28 minutes ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/08/2026
Published on 09/07/2026 at 18:05, 10 hours 28 minutes ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/08/2026

View all LES ECHOS COMFI WIRE